Granuloma formation within media. CD4 + T cells secrete IFN-γ and TNF-α which together are responsible for recruitment of macrophages. ... Giant cell arteritis (GCA) ...

A common medication already used for autoimmune diseases such as rheumatoid arthritis is effective for patients with giant ...

Upadacitinib 15 mg — but not 7.5 mg — alongside a glucocorticoid taper demonstrated superior efficacy to placebo with a ...

“While the phase 3 results of GCAptAIN did not replicate the positive outcomes observed in the phase 2 trial, we remain committed to continuing to drive scientific progress and deepening the ...

SHREVEPORT, La. - Giant cell arteritis, also known as temporal arteritis, is a less common condition where people get inflammation of the arteries that go to the head and neck.

Causes of Giant Cell Arteritis (Temporal Arteritis):Giant Cell Arteritis is an autoimmune disorder where the immune system mistakenly attacks healthy blood vessels, leading to inflammation. While ...

Cosentyx missed its main goal in a Phase 3 GCA study, but showed lower steroid use. Novartis plans full review of the trial ...

Source Reference: Goulabchand R, et al "Burden, causes and outcomes of hospitalization in patients with giant cell arteritis: a US national cohort study" Arthritis Care Res 2022; DOI: 10.1002/acr ...

Find the latest Vasculitis and Giant Cell Arteritis news articles, videos, podcasts, and meeting coverage from medical experts and key opinion leaders you trust.

AbbVie (NYSE: ABBV) today announced the U.S. Food and Drug Administration (FDA) has approved RINVOQ® (upadacitinib), 15 mg, once daily, for the treatment of adults with giant cell arteritis (GCA ...

Giant cell arteritis (GCA) and polymyalgia rheumatica (PMR) are linked conditions that occur in the elderly. GCA is a vasculitis of large- and medium-sized vessels causing critical ischemia.